Madrigal Pharmaceuticals, Inc.
MDGL
$531.25
-$8.64-1.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -94.39M | -58.58M | -114.19M | -42.28M | -73.24M |
| Total Depreciation and Amortization | 794.00K | 1.94M | 1.91M | 432.00K | 435.00K |
| Total Amortization of Deferred Charges | 449.00K | 468.00K | 329.00K | 371.00K | 436.00K |
| Total Other Non-Cash Items | 31.58M | 25.18M | 28.70M | 26.10M | 20.93M |
| Change in Net Operating Assets | -105.87M | -102.47M | 163.10M | -31.68M | -37.46M |
| Cash from Operations | -167.44M | -133.46M | 79.85M | -47.05M | -88.89M |
| Capital Expenditure | -3.85M | 390.00K | -857.00K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 196.04M | 27.19M | -206.14M | 47.86M | 163.88M |
| Cash from Investing | 192.19M | 27.58M | -207.00M | 47.86M | 163.88M |
| Total Debt Issued | -- | 0.00 | 350.00M | -- | -- |
| Total Debt Repaid | -- | 0.00 | -121.66M | -- | -- |
| Issuance of Common Stock | 2.33M | 9.94M | 17.74M | 1.74M | 8.64M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -983.00K | -9.42M | -- | -- |
| Cash from Financing | 2.33M | 8.96M | 236.65M | 1.74M | 8.64M |
| Foreign Exchange rate Adjustments | 1.32M | 13.00K | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 28.41M | -96.91M | 109.50M | 2.55M | 83.63M |